Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503935 | 0.91 | SYK (0.48) | SYKPPARACTSSMAPTKLK5 | |
| SCHEMBL1503940 | 0.84 | SYK (0.49) | SYKPPARACTSSMAPTKLK5 | |
| SCHEMBL25401074 | 0.83 | ATM (0.47) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL25401078 | 0.83 | ATM (0.47) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL261847 | 0.83 | SYK (0.48) | SYKCTSSCASP1CTSKCTSL | |
| SCHEMBL263533 | 0.83 | ATM (0.46) | SYKCTSSCTSKCTSLCTSB | |
| SCHEMBL1503938 | 0.82 | SYK (0.49) | SYKPPARACTSSMAPTKLK5 | |
| SCHEMBL10350971 | 0.82 | KLK5 (0.57) | SYKPPARACTSSMAPTKLK5 | |
| SCHEMBL4363469 | 0.82 | SYK (0.57) | SYKPPARACTSSMAPTKLK5 | |
| SCHEMBL4356869 | 0.82 | SYK (0.57) | SYKPPARACTSSMAPTKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | SYK 1228/4885PPARA 3468/4885CTSS 2612/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | SYK 2089/4885PPARA 4308/4885CTSS 2175/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SYK 2089/4885PPARA 4308/4885CTSS 2175/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | SYK 2089/4885PPARA 4308/4885CTSS 2175/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | SYK 1979/4885PPARA 4353/4885CTSS 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.